AbbVie (ABBV) announced that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie. Capstan’s lead asset CPTX2309, currently in Phase 1 for the treatment of B cell-mediated autoimmune diseases, is a tLNP that generates CD19-specific, CD8+ in vivo CAR-T cells. The CAR-T cells are designed to achieve rapid and deep B cell depletion with the aim of achieving durable, drug-free remission. This can be accomplished without the need for lymphodepleting chemotherapy, while also avoiding other challenges associated with conventional ex vivo CAR-T therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Insider Moves: Microsoft, AMD, Boeing, AbbVie, Eli Lilly
- AbbVie, Dow, Kratos, Rocket, Applied Materials: Trending by Analysts
- AbbVie’s Ubrogepant Study: A Potential Game-Changer for Pediatric Migraine Treatment
- AbbVie’s Promising Phase 2 Study on Metastatic Colorectal Cancer Treatment
- AbbVie’s Pediatric Ulcerative Colitis Study: A Potential Game-Changer